Financial Performance - The company's revenue for Q1 2025 was ¥111,204,722.41, a decrease of 23.98% compared to ¥146,276,963.82 in the same period last year[5]. - Net profit attributable to shareholders increased by 7.25% to ¥23,084,866.50 from ¥21,523,763.06 year-on-year[5]. - Basic and diluted earnings per share rose by 7.24% to ¥0.2132 from ¥0.1988 in the previous year[5]. - Total operating revenue for Q1 2025 was CNY 111,204,722.41, a decrease of 24% compared to CNY 146,276,963.82 in the previous period[22]. - The net profit for the current period is 23,067,656.48, an increase of 7.2% compared to 21,523,763.06 in the previous period[23]. - The basic and diluted earnings per share for the current period are both 0.2132, up from 0.1988 in the previous period, reflecting a growth of 2.2%[23]. - The company reported a total profit of 23,647,716.46, slightly up from 23,229,047.36 in the previous period[23]. Cash Flow and Liquidity - The net cash flow from operating activities improved by 66.35%, reaching -¥552,148.66 compared to -¥1,640,883.14 in Q1 2024[5]. - Cash and cash equivalents decreased by 110.28% to -¥21,484,583.39, primarily due to the maturity of financial products[10]. - The cash and cash equivalents at the end of the period stand at 70,257,798.52, down from 568,547,454.88 at the end of the previous period[27]. - Total cash inflow from investment activities is 179,091,865.86, significantly down from 3,527,905,218.34 in the previous period[27]. - The net cash flow from investment activities is -36,794,402.27, compared to a positive flow of 209,416,222.37 in the previous period[27]. Assets and Liabilities - Total assets at the end of Q1 2025 were ¥1,576,012,493.61, reflecting a 1.52% increase from ¥1,552,474,271.14 at the end of the previous year[5]. - Non-current assets totaled CNY 895,845,377.25, up from CNY 861,739,402.58, marking an increase of about 4%[19]. - The total number of common shareholders at the end of the reporting period is 12,047[12]. - The company reported a decrease in total liabilities to CNY 192,768,042.27 from CNY 192,870,734.45, a reduction of about 0.05%[20]. - Short-term borrowings increased to ¥3,478,384.98, marking a 100% rise as a result of additional bank loans[9]. Shareholder Information - The largest shareholder, Linuo Investment Holding Group Co., Ltd., holds 34.39% of shares, totaling 37,240,000 shares, with 27,290,000 shares pledged[12]. - The second-largest shareholder, Wenze Hong, owns 7.76% of shares, amounting to 8,400,000 shares[12]. - The company has a total of 39,438,000 restricted shares, with no shares released during the reporting period[15]. - The company’s major shareholders include several state-owned and non-state-owned entities, indicating a diverse ownership structure[12]. - The company plans to maintain its current shareholder structure until the scheduled release of restricted shares in 2026[15]. - The total number of preferred shareholders at the end of the reporting period is zero, indicating no preferred shares issued[14]. Operational Performance - The company experienced a 36.74% decrease in operating costs, amounting to ¥54,145,854.92, attributed to a reduction in the quantity of products sold[9]. - Total operating costs for the same period were CNY 93,014,492.94, down 25% from CNY 124,459,548.73[22]. - The total operating expenses amount to 81,083,486.09, down from 89,961,054.86 in the previous period, indicating a reduction in costs[26]. - The company reported a significant increase in prepayments by 140.78%, totaling ¥6,795,685.39 due to increased procurement payments[9]. - Non-operating income surged to ¥4,000,321.41, a 100% increase due to additional non-recurring government subsidies received[9]. Market and Strategy - The company has not disclosed any new strategies or market expansions during this reporting period[16]. - The company has not reported any changes in the participation of major shareholders in margin trading activities[13]. - The company’s financial report indicates a stable shareholder base with no significant changes in the top 10 shareholders[12].
科源制药(301281) - 2025 Q1 - 季度财报